SES AUA 2025
SES AUA 2025
SES AUA 2025: Artificial Intelligence Applications in Prostate Cancer Diagnosis and Treatment
- Details
SES AUA 2025: Overall Survival with Darolutamide Versus Placebo in Combination with Androgen Deprivation Therapy and Docetaxel Accounting for Subsequent Therapy: A Sensitivity Analysis from ARASENS
- Details
(UroToday.com) The American Urologic Association (AUA) Southeastern Section (SES) 89th Annual Meeting, held in Nashville, TN, between March 12th and 15th, 2025, was host to a prostate cancer podium session. Zachary Klaassen, MD, MSc, presented a post-hoc sensitivity analysis from the phase III ARASENS trial evaluating the overall survival benefit of darolutamide versus placebo, in combination with androgen deprivation therapy (ADT) plus docetaxel, for patients with metastatic hormone sensitive prostate cancer (mHSPC), after accounting for subsequent therapy received.
SES AUA 2025: Early Longitudinal Outcomes of Black Men Undergoing PSA Screening Following Implementation of a PSA-Based Risk Stratification Algorithm in a Health System-Wide Initiative
- Details
(UroToday.com) The 2025 SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Mahdi Mottaghi discussing early longitudinal outcomes of black men undergoing PSA screening following implementation of a PSA-based risk stratification algorithm in a health system-wide initiative. The PSA test became widely available in 1987, which is a valuable screening tool but requires balancing the risks of overdiagnosis with detecting clinically significant prostate cancer. In 2012, the USPSTF gave a Grade D recommendation (against PSA screening for all men) for prostate cancer screening. The prostate cancer specific mortality rate declined between 1999 and 2011, but plateaued after 2012, however, the slope of the prostate cancer specific mortality decline was steeper before 2012 among Black men. In 2016, the Duke Cancer Institute, in collaboration with the Primary Care network, created a PSA-based screening algorithm for patient risk stratification, considering PSA, age, and race. In 2018, the USPSTF recommendations were escalated to a Grade C rating for prostate cancer screening, recommending patient-physician counseling. This study aimed to report the outcomes of PSA screening among Black men following implementation of the algorithm.
SES AUA 2025: Outcomes of Men with High-Risk Biochemically Recurrent Prostate Cancer who Suspended Enzalutamide Monotherapy Treatment in the Phase 3 EMBARK Study
- Details
(UroToday.com) The 2025 SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Paul Sieber discussing outcomes of men with high-risk biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study. Biochemical recurrence occurs in 20-50% of patients with prostate cancer within 10 years of definitive therapy, which increases the risk of prostate cancer specific mortality. On November 16, 2023, enzalutamide received an FDA label extension for the treatment of nonmetastatic castration-sensitive prostate cancer with high risk biochemical recurrence. This was based on data from the EMBARK trial that showed enzalutamide + leuprolide and enzalutamide monotherapy improved metastasis-free survival versus leuprolide alone in patients with high-risk biochemically recurrent prostate cancer.1 In EMBARK, treatment was suspended in 304 (85.9%) patients who received enzalutamide monotherapy and 240 (67.8%) patients who received leuprolide alone. Outcomes by treatment suspension status were presented at SESAUA 2025.
SES AUA 2025: Phase 1 Trial of Mevrometostat (PF-06821497), a Potent and Selective Inhibitor of EZH2, in CRPC
- Details
(UroToday.com) The 2025 SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Benjamin Garmezy discussing a phase 1 trial of mevrometostat (PF-06821497), a potent and selective inhibitor of EZH2, in CRPC. The proposed mechanism of action for mevrometostat is as follows:
SES AUA 2025: Validation of PAM50 for Predicting Progression in Active Surveillance: Results from the Miami MAST Prospective Clinical Trial
- Details
(UroToday.com) The 2025 SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Jamie Thomas discussing results from the MAST trial assessing the validation of PAM50 for predicting progression in active surveillance. Active surveillance is now a prevalent approach for managing men with low to favorable intermediate-risk prostate cancer. While prostate cancer-related mortality and metastasis are generally low in this group, some patients may experience progression that requires intervention.
SES AUA 2025: PSA Dynamics from the Phase 3 EMBARK Trial: A Post Hoc Analysis
- Details
(UroToday.com) The 2025 SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Paul Sieber discussing a post hoc analysis from the phase 3 EMBARK study assessing PSA dynamics. FDA approval of enzalutamide for treatment of non-metastatic CSPC with biochemical recurrence at high risk for metastasis, was based on data from the EMBARK trial.
SES AUA 2025: American Urological Association Annual Census Identifies 39% of Practicing Urologists Utilize Unhealthy Coping Mechanisms for Burnout and Stress
- Details
(UroToday.com) The 2025 SESAUA annual meeting featured a health services research session and a presentation by Sydney Strup discussing the American Urological Association’s annual census data assessing coping mechanisms for burnout and stress. In the United States, there is a physician workforce shortage that is likely a cause of physician burnout, which can lead to worse patient outcomes, lower retention, and decreased clinical hours.
SES AUA 2025: Incidence of New Mental Health Diagnoses in Testicular Cancer Survivors
- Details
(UroToday.com) The 2025 SESAUA annual meeting featured a testicular cancer session and a presentation by Dr. Siddharth Marthi discussing the incidence of new mental health diagnoses in testicular cancer survivors. Following a new cancer diagnosis, patients are at risk of being diagnosed with a mental health disorder. The presence of a mental health disorder is associated with longer hospital stays, decreased adherence to treatment recommendations, and worse disease-specific survival. As testicular cancer is very curable, survivorship and quality-of-life considerations are of particular importance. The aim of this study presented at SESAUA 2025 was to evaluate the incidence of and risk factors for mental health disorders in patients after orchiectomy for testicular cancer.
SES AUA 2025: Efficacy and Safety of Darolutamide plus Androgen Deprivation Therapy in Patients with Metastatic Hormone-Sensitive Prostate Cancer from the Phase 3 ARANOTE Trial
- Details
(UroToday.com) The American Urologic Association (AUA) Southeastern Section (SES) 89th Annual Meeting held in Nashville, TN, between March 12th and 15th, 2025, was host to a prostate cancer poster session. Dr. Zachary Klaassen presented the results of the phase III ARANOTE trial evaluating the efficacy and safety of doublet darolutamide plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) patients.
SES AUA 2025: Germline Testing for Renal Cancers – How Age and Tumor Characteristics Affect Pathogenic Variants
- Details
(UroToday.com) The 2025 SESAUA annual meeting featured a kidney cancer session and a presentation by Dr. Robert Smith discussing how age and tumor characteristics affect pathogenic variants in germline testing for renal cancers. Dr. Smith started by highlighting that germline mutations are (i) hereditary, (ii) affect every cell in the body, (iii) are inherited or mutated early in the germinal phase of development, and (iv) can increase a patient’s likelihood of developing a future cancer. Current NCCN guidelines have many criteria for germline testing of individuals with renal tumors including family history, age, and tumor characteristics. When recommending germline testing to patients, we are often asked about the frequency of pathogenic variants, and how these variants affect care. Prior studies have suggested that 3-16% of renal tumors have a pathogenic germline mutation, with common variants including CHEK2, VHL, ATM, BRCA1/2, and PTEN. Dr. Smith and colleagues sought to explore how each of these guideline recommendations affects the rate of return of pathogenic variants among patients undergoing germline testing for renal cancers.
SES AUA 2025: Identifying Key Mutations Linked to Metastasis in Clear Cell Renal Cell Carcinoma: A GENIE Database Analysis
- Details
(UroToday.com) The 2025 SESAUA annual meeting featured a kidney cancer session and a presentation by Reynier Rodriguez Rosales discussing a GENIE database analysis identifying key mutations linked to metastasis in clear cell renal cell carcinoma. Clear cell renal cell carcinoma is characterized by heterogeneity in its genetic landscape, with some mutations potentially contributing to metastasis:
SES AUA 2025: Evaluation of Systemic Therapy and Surgical Consolidation in Patients with Node Positive UTUC
- Details
(UroToday.com) The 2025 SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. Joon Kyung Kim discussing an evaluation of systemic therapy and surgical consolidation in patients with node positive upper tract urothelial carcinoma. The recommended treatment for high-grade upper tract urothelial carcinoma includes radical nephroureterectomy with regional lymph node dissection for clinically organ-confined disease. The timing of peri-operative systemic therapy is multifactorial, with extrapolation of data from muscle-invasive bladder cancer in the neoadjuvant setting, and level 1 data for upper tract urothelial carcinoma in the adjuvant setting based on the POUT trial.1 The timing of peri-operative systemic therapy and need for surgical consolidation in the clinically node positive setting is even more unclear. The goal of this study presented at SESAUA 2025 was to compare survival in clinically node positive patients managed with neoadjuvant, adjuvant, and systemic therapy alone approaches.
SES AUA 2025: Association of Somatic Gene Mutations in Urothelial Cancer Based on Location in the Bladder
- Details
(UroToday.com) The 2025 SESAUA annual meeting featured a bladder cancer session and a presentation by Arjun Venkatesh discussing the association of somatic gene mutations in urothelial cancer based on location in the bladder. Although the size, grade and stage of bladder cancer have proven prognostic significance, the clinical significance of location is less clear. Plausibly, tumors in the lateral wall near the ureteral orifices may have a different etiology and clinical behavior compared to urothelial cancers at the dome. At the 2025 SESAUA, the investigators reported the results of an exploratory analysis of differences in somatic genetic mutations based on location of the tumor in the bladder to gain additional insights into the differences in etiology.
SES AUA 2025: Development and Initial Experience of a Dedicated Female Bladder Cancer Clinical Care Coordinator Role
- Details
(UroToday.com) The 2025 SESAUA annual meeting featured a bladder cancer session and a presentation by Bree Duncan discussing development and initial experience of a dedicated female bladder cancer clinical care coordinator role. Although the majority of bladder cancer patients are male, women present with higher stage disease and have higher perioperative mortality.
SES AUA 2025: Multicenter Experience with First-Line Intravesical Gemcitabine + Docetaxel versus BCG for high risk NMIBC
- Details
(UroToday.com) The 2025 SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. Gabrielle Yankelevich discussing a multicenter experience with first-line intravesical gemcitabine + docetaxel versus BCG for high risk non-muscle invasive bladder cancer.
SES AUA 2025: Systemic Therapy for Renal Cell Carcinoma with a Tumor Thrombus: Management and Outcomes from the Intercontinental Collaboration on Renal Cell Carcinoma Database
- Details
(UroToday.com) The 2025 SESAUA annual meeting featured a kidney cancer session and a presentation by Dr. Maxwell Sandberg discussing results from a study of the Intercontinental Collaboration on Renal Cell Carcinoma Database assessing systemic therapy for renal cell carcinoma with tumor thrombus.
SES AUA 2025: ENVISION: Primary Chemoablation of Recurrent Low-Grade Intermediate Risk NMIBC with UGN-102: A Single-Arm, Open-Label, Phase 3 Trial
- Details
(UroToday.com) The 2025 SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. William Huang discussing results from the ENVISION trial assessing primary chemoablation of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer with UGN-102. Low-grade, intermediate-risk, non-muscle invasive bladder cancer is a persistent and recurrent cancer that is inadequately controlled by the current standard of care, TURBT.
SES AUA 2025: LEGEND: Phase 1/2 Study of Detalimogene Voraplasmid, a Novel, Investigational, Non-Viral Intravesical Gene Therapy for BCG-Unresponsive NMIBC with CIS
- Details
(UroToday.com) The 2025 SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. Shreyas Joshi discussing LEGEND, a phase 1/2 study of detalimogene voraplasmid, a novel, investigational, non-viral intravesical gene therapy for BCG-unresponsive non-muscle invasive bladder cancer with CIS. Bladder sparing therapies for high risk NMIBC address an important unmet need:
SES AUA 2025: Oncologic Efficacy of Reduced versus Standard-Dose BCG for NMIBC
- Details
(UroToday.com) The 2025 SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. Meredith Bernhard discussing the oncologic efficacy of reduced versus standard-dose BCG for non muscle invasive bladder cancer. Intravesical BCG remains a mainstay of treatment for intermediate and high-risk non-muscle invasive bladder cancer, however, since 2012 there has been a global BCG shortage. Various management approaches have been recommended to navigate this shortage, including administering reduced doses, if feasible. With the global BCG shortage projected to last at least several more years, understanding if, when, and how to split BCG vials is crucial for practitioners to effectively treat patients with intermediate and high risk non-muscle invasive bladder cancer. The goal of this study presented at SESAUA 2025 was to compare the oncologic outcomes between patients receiving standard (50 mg) and reduced-dose (25 mg) intravesical BCG.